Big data and AI specialist Palantir Technologies PLTR is gaining significant momentum with its Artificial Intelligence ...

Vertex executed well in the first quarter, getting 2025 off to a strong start. The consistency of our business, which we highlighted during our Investor Day in March, continued as expected.

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Vertex Pharmaceuticals ... you’re backed by our ironclad 30-day money-back guarantee.

The S&P 500 slipped 0.8% on Tuesday, May 6, 2025, falling for a second straight day as investors awaited news on U.S. tariff policies and prepared for tomorrow’s Federal Reserve announcement.

After a rough start to the year, small- and mid-cap software stocks may be finding their footing. Goldman Sachs analyst Adam Hotchkiss says first-quarter results across his coverage were better than ...

Stakeholders agree that the regulatory overhaul sends a strong signal to both local and international investors, positioning ...

Shares of Vertex Pharmaceuticals (VRTX ... Dow Rise for 6th Consecutive Day as Stock Investors Digest Earnings Barrage, Tariff News Markets News, May 8, 2025: Stocks Close Higher After Trump ...

Broadcom's stock has seen a dramatic decline of almost 22% from its recent high in December 2024, driven by escalating market fears due to trade wars between the U.S. and China. Yet, the stock remains ...

With a better upfront offer on the table, enough bluebird bio investors have tendered their shares for the company's sale to ...

The reason is the invalidation of the breakout above the declining resistance line based on the March and late-April highs.